JPWO2022181797A1 - - Google Patents
Info
- Publication number
- JPWO2022181797A1 JPWO2022181797A1 JP2023502560A JP2023502560A JPWO2022181797A1 JP WO2022181797 A1 JPWO2022181797 A1 JP WO2022181797A1 JP 2023502560 A JP2023502560 A JP 2023502560A JP 2023502560 A JP2023502560 A JP 2023502560A JP WO2022181797 A1 JPWO2022181797 A1 JP WO2022181797A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021030812 | 2021-02-26 | ||
| PCT/JP2022/008036 WO2022181797A1 (ja) | 2021-02-26 | 2022-02-25 | 糖尿病および合併症の新規治療、診断および検出のための方法および剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022181797A1 true JPWO2022181797A1 (https=) | 2022-09-01 |
| JPWO2022181797A5 JPWO2022181797A5 (https=) | 2024-01-31 |
Family
ID=83049251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502560A Pending JPWO2022181797A1 (https=) | 2021-02-26 | 2022-02-25 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240139129A1 (https=) |
| EP (1) | EP4299076A4 (https=) |
| JP (1) | JPWO2022181797A1 (https=) |
| KR (1) | KR20230152099A (https=) |
| CN (1) | CN117750976A (https=) |
| AU (1) | AU2022225981A1 (https=) |
| IL (1) | IL305464A (https=) |
| WO (1) | WO2022181797A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312393A (en) * | 2021-10-29 | 2024-06-01 | Biozipcode Inc | A method or factor with an HDAC regulator, for the treatment of diabetes and complications |
| CN118161493B (zh) * | 2024-05-14 | 2024-08-09 | 南昌大学第一附属医院 | 恩替诺特在制备治疗耐药非小细胞肺癌的药物中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08509203A (ja) * | 1992-10-15 | 1996-10-01 | ダナ−ファーバー キャンサー インステテュート インコーポレイテッド | ＴＮＦ−α作用の拮抗剤を用いる肥満関連糖尿病▲ＩＩ▼型のインスリン耐性の治療 |
| JP2009542197A (ja) * | 2006-07-06 | 2009-12-03 | メルク セローノ ソシエテ アノニム | Ｃｓｆ３ｒポリペプチド及びそれらの使用 |
| JP2010508265A (ja) * | 2006-10-30 | 2010-03-18 | ドン・ア・ファーム・カンパニー・リミテッド | Ｇ−ｃｓｆを含有する、糖尿性末梢神経病予防および治療剤 |
| JP2010538275A (ja) * | 2007-08-31 | 2010-12-09 | マサチューセッツ インスティテュート オブ テクノロジー | 自己免疫疾患の処置 |
| WO2013073698A1 (ja) * | 2011-11-17 | 2013-05-23 | 公益財団法人東京都医学総合研究所 | Cxcr4活性阻害ペプチド及びその用途 |
| JP2019509988A (ja) * | 2016-02-05 | 2019-04-11 | ヤンセン バイオテツク，インコーポレーテツド | １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021030812A (ja) | 2019-08-21 | 2021-03-01 | 株式会社 商船三井 | 船舶 |
| CN114828890A (zh) * | 2019-10-18 | 2022-07-29 | 比奥兹普科德公司 | 使用了干细胞迁移剂的糖尿病治疗 |
-
2022
- 2022-02-25 KR KR1020237032953A patent/KR20230152099A/ko active Pending
- 2022-02-25 CN CN202280030689.5A patent/CN117750976A/zh active Pending
- 2022-02-25 US US18/548,023 patent/US20240139129A1/en active Pending
- 2022-02-25 AU AU2022225981A patent/AU2022225981A1/en not_active Abandoned
- 2022-02-25 WO PCT/JP2022/008036 patent/WO2022181797A1/ja not_active Ceased
- 2022-02-25 EP EP22759831.5A patent/EP4299076A4/en active Pending
- 2022-02-25 IL IL305464A patent/IL305464A/en unknown
- 2022-02-25 JP JP2023502560A patent/JPWO2022181797A1/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08509203A (ja) * | 1992-10-15 | 1996-10-01 | ダナ−ファーバー キャンサー インステテュート インコーポレイテッド | ＴＮＦ−α作用の拮抗剤を用いる肥満関連糖尿病▲ＩＩ▼型のインスリン耐性の治療 |
| JP2009542197A (ja) * | 2006-07-06 | 2009-12-03 | メルク セローノ ソシエテ アノニム | Ｃｓｆ３ｒポリペプチド及びそれらの使用 |
| JP2010508265A (ja) * | 2006-10-30 | 2010-03-18 | ドン・ア・ファーム・カンパニー・リミテッド | Ｇ−ｃｓｆを含有する、糖尿性末梢神経病予防および治療剤 |
| JP2010538275A (ja) * | 2007-08-31 | 2010-12-09 | マサチューセッツ インスティテュート オブ テクノロジー | 自己免疫疾患の処置 |
| WO2013073698A1 (ja) * | 2011-11-17 | 2013-05-23 | 公益財団法人東京都医学総合研究所 | Cxcr4活性阻害ペプチド及びその用途 |
| JP2019509988A (ja) * | 2016-02-05 | 2019-04-11 | ヤンセン バイオテツク，インコーポレーテツド | １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用 |
Non-Patent Citations (11)
| Title |
|---|
| AN, J. ET AL.: "Trichostatin A increases BDNF protein expression by improving XBP-1s/ATF6/GRP78 axis in Schwann cell", BIOMED PHARMACOTHER, vol. 133, no. 111062, JPN6022016369, January 2021 (2021-01-01), pages 1 - 14, ISSN: 0005802138 * |
| BROOKS, M.B.: "Erlotinib and Gefitinib, Epidermal Growth Factor Receptor Kinase Inhibitors, May Treat Non-Cancer-Re", ONCOLOGIST, vol. 18, JPN6020047042, 2013, pages 3 - 5, ISSN: 0005802140 * |
| COSTA, D.B. ET AL.: "Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib", DIABETES CARE, vol. 29, no. 7, JPN6020047041, 2006, pages 1711, ISSN: 0005802139 * |
| ELGAMAL, D.A. ET AL.: "Ultrastructure characterization of pancreatic beta-cells is accompanied by modulatory effects of the", MOL CELL ENDOCRINOL, vol. 503, no. 110700, JPN6022016367, 2020, pages 1 - 12, ISSN: 0005802136 * |
| EL-SERAFI, A. ET AL.: "The potentiality of histone deacetylase inhibitors for diabetes and obesity", HISTONE MODIFICATION IN THERAPY, vol. 1st Edition, Chapter 14, JPN6022016366, 2020, pages 361 - 371, ISSN: 0005802135 * |
| SHARMA, S. ET AL.: "Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes", PHARMACOL RES, vol. 113, JPN6022016368, 2016, pages 320 - 326, ISSN: 0005802137 * |
| TSUKAMOTO, K. ET AL.: "Administration of Monoclonal Antibodies against Vascular Cell Adhesion Molecule-1/Very Late Antigen-", CELL IMMUNOL, vol. 165, JPN6020047044, 1995, pages 193 - 201, ISSN: 0005802141 * |
| 小島秀人，外5名: "糖尿病の過食には骨髄由来脳内ミクログリアの分化異常が関与する", 再生医療, vol. 15, JPN6022016364, 2016, pages 248, ISSN: 0005802134 * |
| 樫美和子，外2名: "糖尿病における骨髄幹細胞の分化異常−ヒストンデアセチラーゼ遺伝子の発現異常について−", 再生医療, vol. 10, JPN6022016371, 2011, pages 208, ISSN: 0005802143 * |
| 樫美和子，外2名: "糖尿病における骨髄幹細胞の分化異常と糖毒性メモリー", 再生医療, vol. 12, JPN6022016370, 2013, pages 155, ISSN: 0005802142 * |
| 樫美和子，外7名: "骨髄細胞を標的とした糖尿病の完治を目指した治療法の開発", 第20回日本再生医療学会総会 プログラム抄録, JPN6022016372, 26 February 2021 (2021-02-26), ISSN: 0005802144 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4299076A1 (en) | 2024-01-03 |
| US20240139129A1 (en) | 2024-05-02 |
| CN117750976A (zh) | 2024-03-22 |
| WO2022181797A1 (ja) | 2022-09-01 |
| IL305464A (en) | 2023-10-01 |
| KR20230152099A (ko) | 2023-11-02 |
| EP4299076A4 (en) | 2025-04-16 |
| AU2022225981A1 (en) | 2023-10-12 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20230825 |
|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20231212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250219 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250312 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20250319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260421 |